ReWalk Robotics Ltd. Announces Executive and Board Changes

Ticker: LFWD · Form: 8-K · Filed: Sep 4, 2024 · CIK: 1607962

Sentiment: neutral

Topics: executive-changes, board-changes, personnel

TL;DR

ReWalk Robotics shakes up C-suite and board: new CMO, new director, CFO out.

AI Summary

On September 4, 2024, ReWalk Robotics Ltd. filed an 8-K report detailing several key events. The company announced the appointment of Dr. Alon S. Ziv as Chief Medical Officer and the election of Ms. Yael G. Bar-Lev to its Board of Directors. Additionally, the filing disclosed the departure of Mr. David M. Rehen as Chief Financial Officer and the resignation of Mr. Jonathan M. Miller from the Board of Directors.

Why It Matters

These changes in key leadership positions and the board of directors can impact the company's strategic direction, operational execution, and investor confidence.

Risk Assessment

Risk Level: medium — Changes in executive and board leadership can introduce uncertainty regarding future strategy and performance.

Key Players & Entities

FAQ

Who has been appointed as the new Chief Medical Officer for ReWalk Robotics Ltd.?

Dr. Alon S. Ziv has been appointed as the new Chief Medical Officer.

Who has been elected to the Board of Directors of ReWalk Robotics Ltd.?

Ms. Yael G. Bar-Lev has been elected to the Board of Directors.

Who has departed from the role of Chief Financial Officer at ReWalk Robotics Ltd.?

Mr. David M. Rehen has departed from the role of Chief Financial Officer.

Who has resigned from the Board of Directors of ReWalk Robotics Ltd.?

Mr. Jonathan M. Miller has resigned from the Board of Directors.

What is the exact date of this 8-K filing?

The exact date of this 8-K filing is September 4, 2024.

Filing Stats: 1,220 words · 5 min read · ~4 pages · Grade level 10.6 · Accepted 2024-09-04 17:39:27

Filing Documents

07 Submission of Matters to a Vote of Security Holders

Item 5.07 Submission of Matters to a Vote of Security Holders. ReWalk Robotics Ltd. (the "Company") held its 2024 Annual Meeting of Shareholders (the "Meeting") on September 4, 2024. An aggregate of 4,206,883 ordinary shares, or approximately 48.25% of the Company's 8,719,265 ordinary shares issued and outstanding as of July 24, 2024, the record date for the Meeting, were present or voted at the Meeting, constituting a quorum. The following proposals were voted upon at the Meeting, with the results of such voting as set forth below. Proposals No. 1.a, 1.b, 2 and 7 received the requisite level of approval by shareholders. All other proposals did not receive the requisite level of support. The proposals are described in greater detail in the Company's definitive proxy statement on Schedule 14A, filed with the Securities and Exchange Commission ("SEC") on July 29, 2024 (the "Proxy Statement"). Results of the Meeting Proposal No. 1.a: To reelect Hadar Levy as a Class I director of the Board, to serve until the 2027 annual meeting of shareholders and until his successor has been duly elected and qualified, or until his office is vacated in accordance with the Company's Articles of Association or the Israel Companies Law, 5759-1999 . Nominee For Against Abstain Broker Non-Votes Hadar Levy 2,134,828 94,075 95,771 1,882,209 Proposal No. 1.b: To reelect Joseph Turk as a Class I director of the Board, to serve until the 2027 annual meeting of shareholders and until his successor has been duly elected and qualified, or until his office is vacated in accordance with the Company's Articles of Association or the Israel Companies Law, 5759-1999 . Nominee For Against Abstain Broker Non-Votes Joseph Turk 1,975,082 253,505 96,087 1,882,209 Proposal No. 2: To approve the change of the Company's name to "Lifeward Ltd." or such similar name as the Board of Directors shall determine and as shall be approved by the Israel Registrar of Companies, and t

01 Other Events

Item 8.01 Other Events. As previously disclosed, on June 27, 2024, Jeff Dykan, who served as a Class I director of the Board of the Company and chairperson of the Board, notified the Board that he will retire and not stand for reelection at the Meeting. The departure of Mr. Jeff Dykan from the Board became effective immediately upon closing of the Meeting. In addition, as previously disclosed, on June 27, 2024, the Board approved the appointment of Joseph Turk as chairperson of the Board, effective as of the Meeting.

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ReWalk Robotics Ltd. By: /s/ Michael Lawless Name: Michael Lawless Title: Chief Financial Officer Dated: September 4, 2024

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing